← Evidence map

TrialBritish journal of clinical pharmacology1999

Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism.

T Tateishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

11 papers cite it

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

1999

this papercites it

Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. | OpenQuestion